Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin

References

• Centers for Disease Control. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf [Last accessed 14 February 2006]
   Google Scholar
• American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:935-82
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-9
   PubMed Web of Science ®Google Scholar
• Gerstein H, Yale J, Harris S, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-42
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Lüddeke H, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:659-65
   PubMed Web of Science ®Google Scholar
• Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
   PubMed Web of Science ®Google Scholar
• Raccah D, Bretzel RG, Owens D, et al. When basal insulin therapy in type 2 diabetes mellitus is not enough – what next?. Diabetes Metab Res Rev 2007;23:257-64
   PubMed Web of Science ®Google Scholar
• Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-43
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Cavallucci S. The top 200. What's making waves in prescription sales. Pharm Pract 2006;22:44-9
   Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metabol Res Rev 2009;25:252-8
   Google Scholar
• Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
   PubMed Web of Science ®Google Scholar
• Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009;63:425-32
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
   PubMed Web of Science ®Google Scholar
• Borah BJ, Darkow T, Bouchard J, et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Therapeut 2009;31:623-31
   PubMed Web of Science ®Google Scholar
• Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-3
   PubMedGoogle Scholar
• Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
   PubMed Web of Science ®Google Scholar
• Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259-64
   PubMed Web of Science ®Google Scholar
• Asche CV, McAdam-Marx C, Shane-McWhorter L, et al. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:638-45
   PubMed Web of Science ®Google Scholar
• Oderda G, Lieberman M, Asche C, et al. Use of electronic medical record (EMR) data in outcomes research. Value Health 2007;10:A450-1
   Web of Science ®Google Scholar
• McAdam-Marx C, Bouchard J, Aagren M, et al. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting. Diabetes Obes Metabol 2009;epub ahead of print:16 Sept, 2009
   Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar